P53 Immunohistochemistry Abnormal Staining in Endometrial Cancer

Endometrial Cancer Clinical Trial

Official title:

P53 Immunohistochemistry Abnormal Staining in Endometrial Cancer and Its Relation With Disease Stages, Pathological Types and Grading

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05542940
• Other study ID #: SOKKARY9
• Status: Completed
• Start date: January 1, 2020
• Est. completion date: August 31, 2022

Study information

• Verified date: September 2022
• Source: Alexandria University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Objective: Calculate the incidence of P53 immunohistochemistry abnormal staining in endometrial cancer and to identify its relation with disease stages, pathological types and grading.

Patients and methods:

100 cases of endometrial cancer will be included in the study, recruited from Alexandria university hospital gyne-oncology unit. Surgical staging, histopathological examination and immunohistochemistry of p53 were done to all cases to calculate the incidence of P53 immunohistochemistry abnormal staining in endometrial cancer and to identify its relation with disease stages, pathological types, grading.

Keywords: P53 immunohistochemistry, endometrial cancer, clinicopathological relation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: August 31, 2022
• Est. primary completion date: August 31, 2022
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• endometrial cancer patients

Exclusion Criteria:

• patients unfit for surgery

Related Conditions & MeSH terms

• Endometrial Cancer
• Endometrial Neoplasms

Intervention

Other:
• p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading
p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading

Locations

Country	Name	City	State
Egypt	Hossam Hassan El Sokkary	Alexandria

Sponsors (1)

Lead Sponsor	Collaborator
Hossam Hassan Aly Hassan El Sokkary

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	p53 immunohistochemistry	Incidence of abnormal staining of p53 in endometrial cancer	1 month
Primary	Relation of p53 abnormal staining with disease stages	Relation of p53 abnormal staining with disease stages	1month
Primary	Relation of p53 abnormal staining with disease pathological types	Relation of p53 abnormal staining with disease pathological types	1 month
Primary	Relation of p53 abnormal staining with disease pathological grades	Relation of p53 abnormal staining with disease pathological grades	1 month